Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CIMAB S.A.
China At ASCO: Biotech Pharma, Akeso, Chongqing Precision Showcase Promising Data
EGFR-targeting antibody, anti-PD-1/CTLA4 bispecific antibody and CD19-targeting CAR-T therapy from emerging Chinese oncology companies shine at one of ASCO’s most-watched sessions.
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.
Biocon Upbeat As It Tries To Undercut Roche On Herceptin
India’s Biocon has high expectations for its Herceptin biosimilar, but patient groups are vocal in their criticism of the drug’s price in comparison to Roche’s.
Deals Shaping The Medical Industry, January 2013
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.
- Other Names / Subsidiaries
- InnoMab PTE Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.